Trials / Terminated
TerminatedNCT01820962
Concentrated Citrate Locking to Reduce the Incidence of CVC-related Complications in Hematological Patients
Concentrated Citrate Locking to Reduce the Incidence of Central Venous Catheter-related Infections and Thrombosis: a Randomized Phase III Study in a Hematological Patient Population
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 212 (actual)
- Sponsor
- Maastricht University Medical Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Patients with a hematological malignancy who are undergoing intensive chemotherapy need a central venous catheter (CVC)during their treatment. CVCs are locked with heparin when they are not used. The purpose of this study is to determine whether concentrated citrate locking, compared to heparin, reduces the incidence of central venous catheter-related thrombosis and infections in patients with hematological malignancies undergoing intensive chemotherapy.
Detailed description
Central venous catheter (CVC)-related thrombosis and infections are frequently occurring complications and may cause significant morbidity in patients with hematological malignancies. Interventions to decrease fibrin deposition have the potential to reduce CVC-related thrombosis and infections. At present heparin is most often used as locking solution for central venous catheters in hematological patients despite a lack of evidence regarding the efficacy and safety. Trisodium citrate (TSC) had been shown to be an effective antimicrobial catheter locking in hemodialysis patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | heparin | when not in use CVCs are locked with heparin |
| PROCEDURE | concentrated citrate | when not in use the CVC is locked with concentrated citrate |
Timeline
- Start date
- 2006-07-01
- Primary completion
- 2010-12-01
- Completion
- 2012-07-01
- First posted
- 2013-03-29
- Last updated
- 2013-03-29
Locations
2 sites across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT01820962. Inclusion in this directory is not an endorsement.